Ind-Swift Laboratories Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Ind-Swift Laboratories Ltd filed with BSE on 20 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Ind-Swift Laboratories reported Q1 FY27 operating income of ₹186.08 crore, up 21.16% year-on-year, with operating EBITDA more than doubling to ₹33.32 crore and EBITDA margin expanding to 17.91%. Management said the export segment, particularly own-brand sales, grew to 57.20% of quarterly sales from 48% a year earlier, while newly commercialised CDMO partnerships with Viatris, Manx and Arrotex contributed modest revenue in the quarter. Management discussed capacity expansion, capital allocation of approximately ₹250 crore of cash over roughly two to two-and-a-half years, and provided updates on dossier filings, product registrations, and the Samba facility upgrade to EU-GMP and PIC/S standards.
Numbers mentioned
Operating income: ₹186.08 crore (Q1 FY27)
p. 4
“operating income grew 21.16% year-on-year to ₹186.08 crore from ₹153.58 crore in Q1 FY26”
Pardeep Verma, page 4 of the filed PDF · View the filing
Operating EBITDA: ₹33.32 crore (Q1 FY27)
p. 4
“Operating EBITDA improved 2.85x year-on-year to ₹33.32 crore from ₹8.66 crore in the corresponding quarter last year”
Pardeep Verma, page 4 of the filed PDF · View the filing
Operating EBITDA margin: 17.91% (Q1 FY27)
p. 4
“Operating EBITDA margin expanded sharply by 1258 bps year-on-year to 17.91% from 5.33% in Q1 FY26”
Pardeep Verma, page 4 of the filed PDF · View the filing
PAT excluding exceptional item: ₹24.68 crore (Q1 FY27)
p. 4
“PAT excluding exceptional item stood at ₹24.68 crore, a 2.04x year-on-year jump from ₹8.12 crore”
Pardeep Verma, page 4 of the filed PDF · View the filing
PAT margin: 13.26% (Q1 FY27)
p. 4
“PAT margin improved by 827bps year-on-year to 13.26% from 4.99% in the corresponding quarter of the previous year”
Pardeep Verma, page 4 of the filed PDF · View the filing
Export segment share of sales: 57.20% (Q1 FY27)
p. 4
“Our brands within our export segment contributed 57.20% of quarterly sales in Q1 FY27, up sharply from 48% in Q1 FY26”
Pardeep Verma, page 4 of the filed PDF · View the filing
Total dossiers filed: 2,100+
p. 4
“Our total dossiers filed increased to 2,100+, up from 1,915+ previously”
Pardeep Verma, page 4 of the filed PDF · View the filing
Global product registrations: 850-plus
p. 4
“Global product registrations increased to 850-plus, compared with 750-plus previously, expanding the Company's presence across international markets”
Pardeep Verma, page 4 of the filed PDF · View the filing
Ezetimibe + Atorvastatin sales: ₹25 crores (Q1 FY27)
p. 14
“I think we did a sale of approx. ₹25 crores of this molecule only in the first quarter”
Gagan Aggarwal, page 14 of the filed PDF · View the filing
Export gross margin: approx. 55%
p. 5
“In the export business, we are enjoying approx. 55% margins. Gross margins.”
Gagan Aggarwal, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Incremental revenue from CDMO partnerships — ₹200 to ₹220 crore · FY27
stated as an aspiration by Pardeep Verma
p. 3
“These are expected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27, and represent a key milestone in scaling our contract manufacturing business with global generic majors.”
Pardeep Verma, page 3 of the filed PDF · View the filing
Revenue from two Viatris products — ₹100-130 odd crores · two years
stated firmly by Gagan Aggarwal
p. 5
“Yes, we are expecting approx. ₹100-130 odd crores in these two products. Not the entire ₹200 crores in year one. Gradually it will increase.”
Gagan Aggarwal, page 5 of the filed PDF · View the filing
EBITDA margin — 18%
stated firmly by Gagan Aggarwal
p. 6
“Yes, yes, 18% is fully sustainable and we plan if the sales we are able to increase quarter-on-quarter they might go up to 21 to 22%.”
Gagan Aggarwal, page 6 of the filed PDF · View the filing
Capex deployment — ₹250 crores · 2.5 years
stated firmly by Gagan Aggarwal
p. 6
“So that ₹250 crores will be deployed in capex over a period of 2.5 years approx.”
Gagan Aggarwal, page 6 of the filed PDF · View the filing
Revenue target — ₹1200 crores · FY29
stated firmly by Gagan Aggarwal
p. 8
“Sir, not at this stage. Maybe after if we are able to achieve our, overachieve our results this financial year, we may revise this.”
Gagan Aggarwal, page 8 of the filed PDF · View the filing
Export sales — ₹750 crores · FY27
stated as an aspiration by Gagan Aggarwal
p. 8
“The total export sales which we are expecting this year is ₹750 crores. And out of ₹750 crores, approx. 45% would be through the CDMO business.”
Gagan Aggarwal, page 8 of the filed PDF · View the filing
EBITDA margin — 20% · third quarter
stated conditionally by Gagan Aggarwal
p. 13
“Internally, we plan on second quarter, but I don't want to commit so early, but third quarter is what we are fully expecting to increase our EBITDA margins from 18%.”
Gagan Aggarwal, page 13 of the filed PDF · View the filing
Revenue — 900 crores · this year
stated conditionally by Gagan Aggarwal
p. 13
“See we are expecting sir 900 crores this year.”
Gagan Aggarwal, page 13 of the filed PDF · View the filing
Revenue and net profit — minimum ₹1500 crores revenue and net profit of approx ₹200 plus · FY30
stated as an aspiration by Gagan Aggarwal
p. 8
“FY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.”
Gagan Aggarwal, page 8 of the filed PDF · View the filing
Dossiers filed — 2,500 · Q4 this year
stated firmly by Gagan Aggarwal
p. 11
“We should be 400 plus. So from 2100 to 2500 is where we will reach by Q4 of this year.”
Gagan Aggarwal, page 11 of the filed PDF · View the filing
CAGR growth — 20 to 25% · medium term
stated conditionally by Mohit Jangir
p. 11
“So beyond FY27, can we expect this kind of growth rate with EBITDA margins above 18%?”
Mohit Jangir, page 11 of the filed PDF · View the filing
Capacity utilisation — 90% of capacity · by FY29
stated as an aspiration by Gagan Aggarwal
p. 10
“So the plan which we have given till FY29 should be the 90% of capacity which will be used over a period of time.”
Gagan Aggarwal, page 10 of the filed PDF · View the filing
Ibuprofen/Clarithromycin volume growth — double the first quarter volume · Q2 FY27
stated firmly by Gagan Aggarwal
p. 14
“No, there are no complications. The product has been well accepted by them and in this in this second quarter we expect these volumes to grow double than what we did in the first quarter.”
Gagan Aggarwal, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Only about ₹5-6 crore was booked this quarter from Ibuprofen and Clarithromycin granules, with the full ramp expected gradually over two years.
Answered by Gagan Aggarwal
Asked by Aryan Bhatia: What was the CDMO partnership's contribution this quarter and expected growth over the next three years?
p. 5
“And we have just kick-started this project, and sales for only these two molecules were hardly ₹5-6 crores. So, the growth of these molecules will reflect slowly in quarter two and quarter three.”
Gagan Aggarwal, page 5 of the filed PDF · View the filing
The cash will be deployed into capex, including the warehouse, Jammu facility upgrade, and capacity enhancement, over roughly 2.5 years.
Answered by Gagan Aggarwal
Asked by Aryan Bhatia: How will the ₹250 crore cash on the balance sheet be deployed?
p. 5
“On the ₹250 crore cash which is on the books, that will be gradually deployed in the business over a period of 2.5 years' time.”
Gagan Aggarwal, page 5 of the filed PDF · View the filing
Management confirmed the margin is sustainable and could improve further with volume growth.
Answered by Gagan Aggarwal
Asked by Zaki Nasser: Is the 18% EBITDA margin sustainable?
p. 6
“Yes, yes, 18% is fully sustainable and we plan if the sales we are able to increase quarter-on-quarter they might go up to 21 to 22%.”
Gagan Aggarwal, page 6 of the filed PDF · View the filing
Management said there is a tag-along right that would apply whenever the PE holder exits.
Answered by Gagan Aggarwal
Asked by Zaki Nasser: Would the company exit its Synthimed stake alongside the private equity holder?
p. 6
“See, we have a tag-along right with Synthimed, so whenever they exit, we have a tag-along right.”
Gagan Aggarwal, page 6 of the filed PDF · View the filing
Management said it does not want to revise the target early and will revisit it at year-end if results overachieve.
Answered by Gagan Aggarwal
Asked by Hemant Soni: Is the ₹1200 crore FY29 revenue guidance conservative and will it be revised?
p. 8
“Sir, not at this stage. Maybe after if we are able to achieve our, overachieve our results this financial year, we may revise this.”
Gagan Aggarwal, page 8 of the filed PDF · View the filing
Management indicated the third quarter as the more likely timeframe rather than committing to the second quarter.
Answered by Gagan Aggarwal
Asked by Gaurav Shukla: When can EBITDA margin cross 20%?
p. 13
“Internally, we plan on second quarter, but I don't want to commit so early, but third quarter is what we are fully expecting to increase our EBITDA margins from 18%.”
Gagan Aggarwal, page 13 of the filed PDF · View the filing
Management said the primary criterion is a minimum 50-55% gross margin, along with R&D confidence and prior API experience with the molecule.
Answered by Gagan Aggarwal
Asked by Meet Katrodiya: What criteria are used to select CDMO products/customers?
p. 12
“So while selecting the products first point is very clear to us, it should have a minimum 50% of gross margins. That is the starting point, minimum 50 to 55%.”
Gagan Aggarwal, page 12 of the filed PDF · View the filing
Management described a transfer pricing arrangement where the company receives a share of the differential pricing profit.
Answered by Gagan Aggarwal
Asked by Naitik Mohata: What is the profit-sharing arrangement for the Ezetimibe + Atorvastatin molecule with Tiffen-Becker?
p. 14
“We have a partnership with Tiffen-Becker on this molecule. We have agreed on a transfer pricing for this product and at the price which our customer is selling, we get 50% profits thereafter.”
Gagan Aggarwal, page 14 of the filed PDF · View the filing
Risks flagged
Slower pace of announcing overseas partnership agreements due to geopolitical conflict
p. 7
“But too early to say we have signed some agreements with our customers, but since due to the war the pace is a little slow to announce as of now.”
Gagan Aggarwal, page 7 of the filed PDF · View the filing
Revenue targets are subject to completion of capacity expansion
p. 13
“It is subject to capacity expansion also. If we are able to complete that expansion well in advance we might achieve these numbers early, one year in advance.”
Gagan Aggarwal, page 13 of the filed PDF · View the filing
Historical high leverage and litigation following the merger burdened the formulation business
p. 6
“there were some litigation and other expenses which the formulation business was bearing from 1.5 years”
Gagan Aggarwal, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.